

01 FEB 13 PM 2:48

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Novartis			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 701 Pennsylvania Ave. NW Suite 725 City Washington State/Zip (or Country) DC 20004			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name Rachel King	Telephone 202-638-7429	E-mail (optional)	5. Senate ID # 9204-12
7. Client Name <input type="checkbox"/> Self Novartis Corporation	6. House ID # 33589000		

TYPE OF REPORT 8. Year 2000 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____ 11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13	
<p>12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> >> \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$1,240,000.00</u> Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature *Rachel King* Date 2/13/01

Printed Name and Title Rachel King - Senior Vice President Page 1 of 16

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code AGR (one per page)

16. Specific Lobbying issues
See attached, ,

17. House(s) of Congress and Federal agencies contacted Check if None
Department of Agriculture
Environmental Protection Agency
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Muldoon, Joe		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Signature  Date 2/16/01

Printed Name and Title Rachel King - Senior Vice President Page 2 of 16

Registrant Name: Novartis

Client Name: Novartis Corporation

Item	Description	Data
16	Lobbying Issues	Federal Insecticide, Fungicide & Rodenticide Act 59 Fed. Reg. 60412 (11/24/96) Atrazine, Simazine and Cyanazine: Notice of Initiation of Special Review Agricultural Biotechnology Pesticides Food Quality Protection Act Insect Resistance Management Genetically Engineered Crops Agriculture Appropriations Bill Regulatory Reform

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific Lobbying issues
Appropriations: FDA
Administration: Circular A
Appropriations: USDA

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Bumbaugh, Deborah</u>		<u>No</u>
<u>Elkin, James</u>		<u>No</u>
<u>Muldoon, Joe</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Signature  Date _____

Printed Name and Title Rachel King - Senior Vice President Page 4 of 16

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CHM (one per page)

16. Specific Lobbying issues
Food Quality Protection Act
Pesticides

17. House(s) of Congress and Federal agencies contacted Check if None

Department of Agriculture
Environmental Protection Agency
Food & Drug Administration
House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Drake, David		No
Muldoon, Joe		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Signature  Date 2/13/01

Printed Name and Title Rachel King - Senior Vice President Page 5 of 16

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)
16. Specific Lobbying issues
H.R.1907, American Inventors Protection Act of 1999,
H.R.2100, Antitampering Act of 1999,
H.R.2654, American Inventors Protection Act of 1999,
S.1172, Drug Patent Term Restoration Review Procedure Act of 1999,

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Cassery, Dan		No
Drake, David		No
Elkin, James		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit

Signature  Date 2/13/04

Printed Name and Title Rachel King - Senior Vice President Page 6 of 16

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code ENV (one per page)

16. Specific Lobbying issues

H.R.1300, Recycle America's Land Act of 1999,
H.R.1657, Children's Environmental Protection and Right to Know Act of 1999,
S.1090, Superfund Program Completion Act of 1999,
S.1090/H.R. 1300 Superfund Program Completion Act of 1999

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Drake, David</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit

Signature  Date 2/4/01

Printed Name and Title Rachel King - Senior Vice President Page 7 of 16

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code FOO (one per page)
16. Specific Lobbying issues
H.R.1592, Regulatory Fairness and Openness Act of 1999,
H.R.3377, Genetically Engineered Food Right to Know Act.

17. House(s) of Congress and Federal agencies contacted Check if None
Department of Agriculture
Environmental Protection Agency
Food & Drug Administration
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Drake, David		No
Haller, Sarah		No
King, Rachel		No
Muldoon, Joe		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Signature  Date 2/10/01

Printed Name and Title Rachel King - Senior Vice President Page 8 of 16

Registrant Name: Novartis

Client Name: Novartis Corporation

Item	Description	Data
16	Lobbying Issues	S.251, S.860, H.R. 830, H.R. 1145, Country of Origin Labeling S. 1155/H.R. 2129 National Uniformity for Food Act of 1999 59 Fed. Reg. 60412 (11/24/96) Atrazine, Simazine and Cyanazine: Notice of Initiation of Special Review Food Quality Protection Act GMO Labeling Juice HACCP Proposal Regulations USDA Expanded Enforcement

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.


15. General issue area code GOV (one per page)
16. Specific Lobbying Issues
H.R.1778, Federal Election Law Integrity Act of 1999,
S.746, Regulatory Improvement Act of 1999,

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Drake, David</u>		<u>No</u>
<u>King, Rachel</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 2/15/01

Printed Name and Title Rachel King - Senior Vice President Page 10 of 16

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.


15. General issue area code HCR (one per page)
16. Specific Lobbying issues
H.R.4607, Medicare Prescription Drug Act of 2000,
H.R.4680, Medicare Rx 2000 Act,
S.2807, Medicare Prescription Drug and Modernization Act of 2000,

17. House(s) of Congress and Federal agencies contacted Check if None
Drug Enforcement Administration
Food & Drug Administration
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Bumbaugh, Deborah</u>		<u>No</u>
<u>Cassery, Dan</u>		<u>No</u>
<u>Elkin, James</u>		<u>No</u>
<u>Haller, Sarah</u>		<u>No</u>
<u>King, Rachel</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Signature  Date 2/12/01
Printed Name and Title Rachel King - Senior Vice President Page 11 of 16

Registrant Name: Novartis

Client Name: Novartis Corporation

Item	Description	Data
16	Lobbying Issues	<p>Snowe/Wyden The Senior Prescription Insurance Coverage Equity Act Breaux/Thomas Medicare Reform Plan Health Insurance Portability and Accessibility Act FDA Modernization Act Pediatric Studies Program Medical Records Privacy - Senators Jeffords, Bennett, Leahy, Kennedy BBIs Xenotransplantation Prospective Payment System Balanced Budget Refinement Act Gene Therapy Drug Reimportation Medicare Reform BBRA II Agriculture Appropriations 2000 - Drug Reimportation</p>

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code LBR (one per page)

16. Specific Lobbying issues
OSHA Ergonomics Legislation

17. House(s) of Congress and Federal agencies contacted Check if None
Department of Labor
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Drake, David</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 2/13/01

Printed Name and Title Rachel King / Senior Vice President Page 13 of 16

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

H.R.1090, Medicare Full Access to Cancer Treatment Act of 1999,
H.R.1115, Immunosuppressive Drug Coverage Extension Act of 1999,
H.R.1796, Medicare Chronic Disease Prescription Drug Benefit Act of 1999,
H.R.1885/S. 1191, International Prescription Drug Parity Act,
H.R.2030, Medicare Patient Access to Technology Act of 1999,
H.R.3887/S. 2232, Medicare Wellness Act of 2000,
H.R.664/S. 731, Prescription Drug Fairness for Seniors Act of 1999,
S.841, Access to Rx Medications in Medicare Act of 1999 (Kennedy),
Snowe/Wyden Seniors Prescription Insurance Coverage Equity Act

17. House(s) of Congress and Federal agencies contacted Check if None


Department of Health & Human Services
Food & Drug Administration
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Bumbaugh, Deborah		No
Cassery, Dan		No
Drake, David		No
Elkin, James		No
King, Rachel		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Signature  Date 2/12/01

Printed Name and Title Rachel King - Senior Vice President Page 14 of 16

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific Lobbying Issues
R&D Tax Credit
International Tax - FSCs

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Drake, David</u>		<u>No</u>
<u>Haller, Sarah</u>		<u>No</u>
<u>King, Rachel</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Signature  Date 2/16/09

Printed Name and Title Rachel King - Senior Vice President Page 15 of 16

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific Lobbying issues
Economic Sanctions
SRM Ban/RSE
China/World Trade Organization
Fast Track Negotiating Authority

17. House(s) of Congress and Federal agencies contacted Check if None

Department of Commerce
Food & Drug Administration
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Haller, Sarah		No
King, Rachel		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Signature  Date 2/16/01

Printed Name and Title Rachel King - Senior Vice President Page 16 of 16